RaySearch Holds Margin Strength Amid Q1 Slowdown and Sets Higher 2028 Profit Target

RaySearch Laboratories AB ( ($SE:RAY.B) ) just unveiled an update.

RaySearch Laboratories AB, a Swedish medtech firm focused on radiation therapy planning and oncology information systems, markets its RayStation and RayCare software to cancer clinics worldwide. The company targets both established and emerging proton and conventional radiotherapy centers, supporting complex treatment workflows and integration with advanced therapy systems.

In the first quarter of 2026, RaySearch reported declines in order intake, net sales and earnings, but maintained a solid EBIT margin of 23 percent and a strong equity ratio, while continuing to grow its workforce. Operationally, the company advanced its market position with the first RayCare order in China, system replacements at a French radiotherapy institute and clinical adoption in Ukraine, and it underlined confidence in its long-term profitability by introducing a higher operating margin target of at least 30 percent for 2028, despite near-term pressure on growth and cash flow.

More about RaySearch Laboratories AB

RaySearch Laboratories AB is a Swedish medical technology company specializing in advanced software solutions for radiation therapy in cancer treatment. Its flagship products, RayStation for treatment planning and RayCare for oncology information management, are used by cancer centers globally, with a growing presence in markets such as China, Europe and emerging regions.

Average Trading Volume: 184,352

Technical Sentiment Signal: Buy

Current Market Cap: SEK7.56B

For a thorough assessment of RAY.B stock, go to TipRanks’ Stock Analysis page.